Chronic Lymphocytic Leukemia
CRISCurisCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Emavusertib (CA-4948) (IRAK4/FLT3 Inhibitor) in Chronic Lymphocytic Leukemia. The expected timing is based on the latest available company guidance and may change.
11/6/25- Ph2 trial initiated w/ dosing of first patient in late Q4 or early Q1 2026. 03/19/26:- TakeAim CLL Ph2 emavusertib+zanubrutinib study initiated; fifth patient dosing, tied to PIPE warrants, expected later 2026. 05/12/26:- Initial 5-patient dosing expected by Mid-2026; study data readout expected in December 2026. 06/26/26:- TakeAim CLL CA-4948-203 (NCT07271667) opened 11 sites; initial five-patient dosing by end July 2026; data expected December 2026. 07/06/26:- First six patients consented; five-patient dosing reaffirmed by end July 2026. Initial data expected December 2026. 07/22/26:- Ten consented; first five dosed by end July. December 2026 initial data now 5-10 patients. 07/30/26:- First five patients dosed in TakeAim CLL. Initial data in 5-10 patients expected December 2026.
Verification
Confirm timing and program details against the company announcement or filing.